Table 2 Overview of ongoing clinical trials of antibodies for AML

Antibodies targeting tumor-associated antigens

 BI 836858

CD33

BI 836858 + decitabine

AML

II

NCT02632721

 GO

CD33

GO + CPX-351

Relapsed AML

I

NCT03904251

GO + venetoclax

R/R CD33 + AML

I

NCT04070768

GO + pracinostat

R/R CD33 + AML

I

NCT03848754

GO + allo-HCT

Average-risk CD33 + AML or MDS or JMML

I

NCT01020539

GO, midostaurin, cytarabine and daunorubicin

Newly diagnosed FLT3 mutated AML

I

NCT03900949

GO + talazoparib

R/R CD33 + AML

I/II

NCT04207190

GO, midostaurin, cytarabine and daunorubicin

Newly diagnosed AML

I/II

NCT04385290

GO, PF-04518600, venetoclax, avelumab, glasdegib and azacitidine

R/R AML

I/II

NCT03390296

GO, G-CSF, cladribine, cytarabine and mitoxantrone

Newly diagnosed AML

I/II

NCT03531918

GO

CD33 + AML

II

NCT03737955

GO + allo-HCT

Average-risk CD33 + AML or MDS

II

NCT02117297

GO + azacitidine

Newly diagnosed elderly AML

II

NCT00658814

GO + bortezomib

R/R AML

II

NCT04173585

GO + CPX-351

R/R CD33 + AML or high-risk MDS

II

NCT03672539

GO + DLI

R/R AML

II

NCT03374332

GO, mitoxantrone and etoposide

Refractory CD33 + AML

II

NCT03839446

GO, cyclophosphamide, busulfan and allo-HCT

High-risk CD33 + AML or MDS

II

NCT02221310

GO, fludarabine, cytarabine, filgrastim-sndz and idarubicin

Newly diagnosed AML or high-risk MDS

II

NCT00801489

GO, daunorubicin, cytarabine and glasdegib

Newly diagnosed AML

II

NCT04168502

GO + standard chemotherapy

Pediatric AML

II

NCT04326439

GO + cytarabine

Newly diagnosed AML

II/III

NCT02473146

GO + daunorubicin + cytarabine

Elderly AML

II/III

NCT02272478

GO

Newly diagnosed AML

III

NCT04093505

GO + standard chemotherapy

Newly diagnosed NPM1 mutated AML

III

NCT00893399

GO + standard chemotherapy + HCT

AML

III

NCT00049517

GO, CPX-351, gilteritinib and standard chemotherapy

Newly diagnosed AML

III

NCT04293562

GO, liposomal daunorubicin, mitoxantrone, fludarabine, cytarabine, busulfan and cyclophosphamide

Pediatric AML

III

NCT02724163

GO

R/R CD33 + AML

IV

NCT03727750

 Lintuzumab Ac-225

CD33

Lintuzumab Ac-225, cladribine, cytarabine, mitoxantrone and G-CSF

R/R CD33 + AML

I

NCT03441048

Lintuzumab-Ac225 + venetoclax + spironolactone

R/R CD33 + AML

I/II

NCT03867682

Lintuzumab-Ac225 + venetoclax + azacitidine

R/R CD33 + AML

I/II

NCT03932318

 Daratumumab

CD38

Daratumumab

R/R AML or high-risk MDS

II

NCT03067571

Daratumumab + DLI

Relapsed AML after HCT

I/II

NCT03537599

 Isatuximab

CD38

Isatuximab + standard chemotherapy

Pediatric R/R ALL or AML

II

NCT03860844

 Magrolimab

CD47

Magrolimab + atezolizumab

R/R AML

I

NCT03922477

Magrolimab + azacitidine

AML or MDS

I

NCT03248479

Magrolimab + azacitidine + venetoclax

AML

I/II

NCT04435691

 Cusatuzumab

CD70

Cusatuzumab, azacitidine and venetoclax

AML

I

NCT04150887

Cusatuzumab + azacitidine

Newly diagnosed AML or high-risk MDS

I

NCT04241549

Cusatuzumab + azacitidine

Newly diagnosed AML or high-risk MDS

I/II

NCT03030612

Cusatuzumab + azacitidine

Newly diagnosed AML

II

NCT04023526

 SEA-CD70

CD70

SEA-CD70

AML or MDS

I

NCT04227847

 IMGN632

CD123

IMGN632

R/R CD123 + AML or other hematologic malignancies

I/II

NCT03386513

IMGN632, venetoclax and azacitidine

CD123 + AML

I/II

NCT04086264

 ASP1235

FLT3

ASP1235

AML

I

NCT02864290

 FLYSYN

FLT3

FLYSYN

AML

I/II

NCT02789254

 Atezolizumab

PD-L1

Atezolizumab + magrolimab

R/R AML

I

NCT03922477

Atezolizumab + gilteritinib

R/R FLT3 mutated AML

I/II

NCT03730012

Atezolizumab + guadecitabine

R/R AML, CML or MDS

I/II

NCT02935361

 Avelumab

PD-L1

Avelumab, GO, PF-04518600, venetoclax, glasdegib and azacitidine

R/R AML

I/II

NCT03390296

 Durvalumab

PD-L1

Durvalumab + azacitidine

Newly diagnosed MDS or elderly AML

II

NCT02775903

Antibodies targeting NK cell inhibitory receptors

 Pembrolizumab

PD-1

Pembrolizumab

Relapsed AML or MDS after HCT

I

NCT03286114

NCT02981914

Pembrolizumab + decitabine

AML or MDS

I

NCT03969446

Pembrolizumab + AMG 330

R/R AML

I

NCT04478695

Pembrolizumab

Non-favorable risk AML

II

NCT02771197

Pembrolizumab

Elderly AML in remission

II

NCT02708641

Pembrolizumab + cytarabine

R/R AML

II

NCT02768792

Pembrolizumab + azacitidine

NPM1 mutated AML

II

NCT03769532

Pembrolizumab + azacitidine

R/R AML or newly diagnosed elderly AML

II

NCT02845297

Pembrolizumab, azacitidine and venetoclax

Elderly newly diagnosed AML

II

NCT04284787

Pembrolizumab, cytarabine, idarubicin, daunorubicin and HCT

Newly diagnosed AML

II

NCT04214249

 Nivolumab

PD-1

Nivolumab

High-risk AML or MDS after HCT

I

NCT04361058

Nivolumab

Relapsed AML after HCT

I

NCT01822509

Nivolumab + ipilimumab

AML or MDS

I

NCT02846376

Nivolumab + ipilimumab

High-risk R/R AML or MDS

I

NCT03600155

Nivolumab, CDX-1401, poly ICLC and decitabine

AML or MDS

I

NCT03358719

Nivolumab + azacytidine

Pediatric R/R AML

I/II

NCT03825367

Nivolumab

AML in remission at high-risk for relapse

II

NCT02532231

Nivolumab

AML in remission

II

NCT02275533

Nivolumab, azacitidine and ipilimumab

AML

II

NCT02397720

Nivolumab, azacitidine, midostaurin, decitabine and cytarabine

Elderly newly diagnosed AML or high-risk MDS

II/III

NCT03092674

 Tislelizumab

PD-1

Tislelizumab, DNA hypomethylating agent and chemotherapy

AML

II

NCT04541277

 Spartalizumab

PD-1

Spartalizumab, MBG453 and decitabine

AML or high-risk MDS

I

NCT03066648

 Ipilimumab

CTLA-4

Ipilimumab

Relapsed AML after HCT

I

NCT01822509

Ipilimumab + nivolumab

High-risk R/R AML or MDS

I

NCT03600155

Ipilimumab + nivolumab

AML or MDS

I

NCT02846376

Ipilimumab + decitabine

R/R AML or MDS

I

NCT02890329

Ipilimumab + DLI

Relapsed AML, MDS or MPN after HCT

I

NCT03912064

Ipilimumab, nivolumab and azacitidine

AML

II

NCT02397720

 MBG453

TIM-3

MBG453, HDM201 and venetoclax

AML or high-risk MDS

I

NCT03940352

MBG453, spartalizumab and decitabine

AML or high-risk MDS

I

NCT03066648

MBG453, azacitidine and venetoclax

Newly diagnosed AML

II

NCT04150029

BiKE or TriKE

 GTB-3550

CD16/IL-15/CD33

GTB-3550

CD33 + R/R AML or high-risk MDS

I/II

NCT03214666